Media

Fusion Pharmaceuticals Announces Clinical Collaboration With Merck To Evaluate Fusion’s Targeted Alpha Therapy (TAT) In Combination With Merck’s KEYTRUDA® (Pembrolizumab) In Patients With Solid Tumors Expressing IGF-1R

Strongbridge Biopharma plc to Host First Quarter 2021 Financial Results Conference Call on May 12, 2021

Oncopeptides completes patient enrollment in phase 2 PORT study

Interim report January – March 2021

The Norwegian Directorate of Health Chooses Doctrin For Its National Triage Solution

Pulmonx Reports First Quarter 2021 Financial Results

Pulmonx Corporation Expands Leadership Team

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF